CTRI/2022/06/043128尚未招募2 期
A randomized open-label parallel group controlled clinical study to evaluate the efficacy of Jayantyadi churna in the management of sthoulya with special reference to primary obesity
Dr Sarjita Tusharbhai Patel0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects with body mass index range (BMI) between 25 to 34.9 kg/m2.
排除标准
- •1.Pregnant,lactating women.
- •2.Subjects with uncontrolled systemic illness including diabetes mellitus,hypertension.
- •3.Associated with previous positive history of endocrinal disorders such as cushings syndrome,PCOD,hypothyroidism.
- •4.any other condition interfering the course of disease and treatment.
研究者
相似试验
已完成
不适用
An open-label parallel group randomized controlled trial for investigating the efficacy and persistence of internet self-learning and filmed social contact for reducing stigma in the university students.ot applicableJPRN-UMIN000012239The University of Tokyo240
进行中（未招募）
不适用
A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.This study is being performed to investigate the efficacy, safety and tolerability of administration of MIRCERA to anaemic patients with chronic kidney disease and reduced renal function following renal transplant, who are not expected to be considered for dialysis during the course of the study. Hereafter for the purposes of this protocol this population will be referred to as ‘post renal transplant anaemia’ patients.MedDRA version: 9.1Level: PTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-003955-35-DEF. Hoffmann-La Roche Ltd318
进行中（未招募）
不适用
A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.This study is being performed to investigate the efficacy, safety and tolerability of administration of MIRCERA to anaemic patients with chronic kidney disease and reduced renal function following renal transplant, who are not expected to be considered for dialysis during the course of the study. Hereafter for the purposes of this protocol this population will be referred to as ‘post renal transplant anaemia’ patients.MedDRA version: 9.1Level: PTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-003955-35-GBF. Hoffmann-La Roche Ltd318
进行中（未招募）
1 期
A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.post renal transplant anaemia patients.MedDRA version: 9.1Level: PTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-003955-35-FRF. Hoffmann-La Roche Ltd318
进行中（未招募）
1 期
A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.EUCTR2007-003955-35-BEF. Hoffmann-La Roche Ltd318